Literature DB >> 28876947

Integrin-Assisted T-Cell Activation on Nanostructured Hydrogels.

Judith Guasch1,2,3,4, Christine A Muth3,4, Jennifer Diemer3,4, Hossein Riahinezhad3,4, Joachim P Spatz3,4.   

Abstract

Adoptive cell therapy (ACT) has shown very promising results as treatment for cancer in a few clinical trials, such as the complete remissions of otherwise terminal leukemia patients. Nevertheless, the introduction of ACT into clinics requires overcoming not only medical but also technical challenges, such as the ex vivo expansion of large amounts of specific T-cells. Nanostructured surfaces represent a novel T-cell stimulation technique that enables us to fine-tune the density and orientation of activating molecules presented to the cells. In this work, we studied the influence of integrin-mediated cell-adhesion on T-cell activation, proliferation, and differentiation using nanostructured surfaces, which provide a well-defined system at the nanoscale compared with standard cultures. Specifically, we synthesized a polymeric polyethylene glycol (PEG) hydrogel cross-linked with two fibronectin-derived peptides, cyclic Arg-Gly-Asp (cRGD) and cyclic Leu-Asp-Val (cLDV), that are known to activate different integrins. Moreover, the hydrogels were decorated with a quasi-hexagonal array of gold nanoparticles (AuNPs) functionalized with the activating antibody CD3 to initiate T-cell activation. Both cLDV and cRGD hydrogels showed higher T-cell activation (CD69 expression and IL-2 secretion) than nonfunctionalized PEG hydrogels. However, only the cRGD hydrogels clearly supported proliferation giving a higher proportion of cells with memory (CD4+CD45RO+) than naı̈ve (CD4+CD45RA+) phenotypes when interparticle distances smaller than 150 nm were used. Thus, T-cell proliferation can be enhanced by the activation of integrins through the RGD sequence.

Entities:  

Keywords:  Nanostructures; T-cells; hydrogels; integrins; peptides

Mesh:

Substances:

Year:  2017        PMID: 28876947     DOI: 10.1021/acs.nanolett.7b02636

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  8 in total

Review 1.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

Review 2.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 3.  Nanodrugs Targeting T Cells in Tumor Therapy.

Authors:  Maximilian Haist; Volker Mailänder; Matthias Bros
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

4.  Artificial 3D Culture Systems for T Cell Expansion.

Authors:  Eduardo Pérez Del Río; Marc Martinez Miguel; Jaume Veciana; Imma Ratera; Judith Guasch
Journal:  ACS Omega       Date:  2018-05-16

5.  Immunoregulation of macrophages by dynamic ligand presentation via ligand-cation coordination.

Authors:  Heemin Kang; Boguang Yang; Kunyu Zhang; Qi Pan; Weihao Yuan; Gang Li; Liming Bian
Journal:  Nat Commun       Date:  2019-04-12       Impact factor: 14.919

6.  Functionalization of polyacrylamide for nanotrapping positively charged biomolecules.

Authors:  Nadejda Davydova; Xavier R Rodriguez; Carlos Blázquez; Andrés Gómez; Igor Perevyazko; Judith Guasch; Vladimir Sergeev; Elena Laukhina; Imma Ratera; Jaume Veciana
Journal:  RSC Adv       Date:  2019-05-16       Impact factor: 3.361

7.  Nanocarriers for cancer nano-immunotherapy.

Authors:  Isra Rana; Jaeeun Oh; Juwon Baig; Jeong Hyun Moon; Sejin Son; Jutaek Nam
Journal:  Drug Deliv Transl Res       Date:  2022-10-03       Impact factor: 5.671

8.  CD4+ T Cell Interstitial Migration Controlled by Fibronectin in the Inflamed Skin.

Authors:  Ninoshka R J Fernandes; Nicholas S Reilly; Dillon C Schrock; Denise C Hocking; Patrick W Oakes; Deborah J Fowell
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.